Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Les immunothérapies sont l’avenir de la rhumatologie.

Hélène Joubert

Le Quotidien du Médecin. | 2026 Mar 31. Version en ligne. URL : lequotidiendumedecin.fr. Sujets : Immunothérapie ; Rhumatologie ; Maladies auto-immunes.

Une femme guérie de trois maladies auto-immunes grâce à une immunothérapie anticancer.

Anne Prigent

Le Figaro Santé | 2026 Apr 14. Online ahead of print. Sujets : Maladies auto-immunes; Immunothérapie.